Alnylam Pharmaceuticals - ALNY Stock Forecast, Price & News

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals Trading Up 5.4 %

ALNY traded up $11.71 during trading on Monday, hitting $230.29. The company's stock had a trading volume of 47,358 shares, compared to its average volume of 889,481. Alnylam Pharmaceuticals has a twelve month low of $117.58 and a twelve month high of $226.00. The company has a debt-to-equity ratio of 3.85, a current ratio of 3.76 and a quick ratio of 3.62. The stock's fifty day moving average price is $145.22 and its 200-day moving average price is $148.03.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Rating) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.62) by ($0.67). Alnylam Pharmaceuticals had a negative net margin of 110.91% and a negative return on equity of 204.18%. The business had revenue of $224.80 million during the quarter, compared to analyst estimates of $256.06 million. During the same period last year, the firm posted ($1.61) earnings per share. Alnylam Pharmaceuticals's quarterly revenue was up 1.9% compared to the same quarter last year. As a group, sell-side analysts predict that Alnylam Pharmaceuticals will post -8.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on ALNY. Needham & Company LLC lifted their target price on Alnylam Pharmaceuticals from $205.00 to $240.00 and gave the company a "buy" rating in a research report on Thursday. William Blair began coverage on Alnylam Pharmaceuticals in a research report on Tuesday, June 7th. They issued an "outperform" rating on the stock. Cantor Fitzgerald started coverage on Alnylam Pharmaceuticals in a research report on Tuesday, July 12th. They issued a "neutral" rating and a $175.00 target price on the stock. Chardan Capital lifted their price target on Alnylam Pharmaceuticals from $200.00 to $250.00 and gave the company a "buy" rating in a research note on Thursday. Finally, HC Wainwright lifted their price target on Alnylam Pharmaceuticals from $400.00 to $430.00 in a research note on Monday, May 2nd. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $225.75.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,754 shares of the business's stock in a transaction that occurred on Tuesday, July 5th. The stock was sold at an average price of $150.00, for a total transaction of $263,100.00. Following the completion of the sale, the executive vice president now owns 1,754 shares in the company, valued at $263,100. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 5,349 shares of company stock valued at $1,033,073. 1.40% of the stock is currently owned by company insiders.